Nachrichten zu Aditxt

Startseite > Aktien > Aditxt > Nachrichten

Aditxt Aktie

Aktie

ISIN: US0070257037 SYM: ADTX Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

1,3840

USD

-6,48 %

-0,0959 USD

Letzter Kurs 22:30:00 NYSE

Geldkurs

22:02:00

1,3500

USD

200 STK

Briefkurs

22:02:00

1,4400

USD

200 STK

Aditxt Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem 14:15 Uhr · Business Wire (engl.) · Evofem Biosciences
Aditxt Delivers Shareholder Update and 2024 Year-End Plan 03.10.24 · Business Wire (engl.) · Evofem Biosciences
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 27.09.24 · Business Wire (engl.) · Aditxt
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt 24.09.24 · Business Wire (engl.) · Evofem Biosciences
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 20.09.24 · Business Wire (engl.) · Evofem Biosciences
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 09.09.24 · Business Wire (engl.) · Evofem Biosciences
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic Prostate Test, Targeting Early Detection in High-Risk Patients 04.09.24 · Business Wire (engl.) · Aditxt
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 29.08.24 · Business Wire (engl.) · Evofem Biosciences
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic Endometriosis Test (MET) and Mitomic Prostate Test (MPT) 26.08.24 · Business Wire (engl.) · Aditxt
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics 21.08.24 · Business Wire (engl.) · Aditxt
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans 13.08.24 · Business Wire (engl.) · Aditxt
Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules 09.08.24 · Business Wire (engl.) · Aditxt

1
2
…
3

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With ... 104 Leser

Aditxt Delivers Shareholder Update and 2024 Year-End Plan 164 Leser
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With ... 104 Leser

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt 280 Leser
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of ... 176 Leser
Aditxt Delivers Shareholder Update and 2024 Year-End Plan 164 Leser
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of ... 152 Leser
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 108 Leser
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With ... 104 Leser

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of ... 1312 Leser
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt 280 Leser
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing 204 Leser
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of ... 176 Leser
Aditxt Delivers Shareholder Update and 2024 Year-End Plan 164 Leser
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of ... 152 Leser
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense ... 152 Leser
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules 128 Leser
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary ... 120 Leser
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules 120 Leser